<DOC>
	<DOCNO>NCT02166788</DOCNO>
	<brief_summary>BACKGROUND : Spread metastatic melanoma groin lymph node ( LN ) common event affect 350 people year Australia . Globally show patient involve groin LN , without proven pelvic LN disease image receive 1 3 management strategy equal proportion - inguinal lymphadenectomy ( IL ) ; ilio-inguinal lymphadenectomy ( I-IL ) ; variable use either depend circumstance . Different expert strong polarised opinion favour either IL extensive I-IL exist case series report conflict data best cancer outcome . No high level evidence prove operation best . HYPOTHESIS : There significant difference DFS patient IL I-IL , conditional PET/CT scan show evidence pelvic disease time diagnosis groin LN metastatic melanoma . AIMS : To provide rational evidence base management melanoma groin LNs randomly assess effect operation DFS , distant DFS , overall survival ( OS ) , morbidity - include early complication longer-term rate lymphedema well comprehensively assess QOL . Also clarify reliability PET/CT scan stag pelvic LNs evaluate health economic benefit I-IL IL . TARGET POPULATION : To recruit 634 patient 5 year . DESIGN : An Australian led , international , multi-centre , non-inferiority , phase III , prospective , randomise clinical trial compare IL I-IL patient metastatic melanoma groin LNs evidence pelvic disease PET/CT . ENDPOINTS : DFS , Distant DFS , OS QOL 5 year . Accuracy PET/CT pelvic LN metastasis . OUTCOMES : International standardization care , improve cancer outcome , improve QOL patient groin metastatic melanoma . Proof principle extent surgery PET/CT clear adjacent LN area , lead clinical trial investigate management lymph node field .</brief_summary>
	<brief_title>Evaluation Groin Lymphadenectomy Extent For Metastatic Melanoma</brief_title>
	<detailed_description>Background Rationale Spread metastatic melanoma groin lymph node ( LN ) common event patient melanoma . In melanoma treatment centre around world , patient without demonstrated pelvic LN disease receive 1 3 strategy management relatively equal proportion ( Pasquali , Spillane et al . 2012 ) : i. Inguinal Lymphadenectomy ( IL ) ii . Ilio-inguinal Lymphadenectomy ( I-IL ) iii . Variable use either IL I-IL surgery . Some large melanoma centre institutional policy patient either IL I-IL metastatic inguinal node involvement . Nearly centre would agree patient pelvic LN involvement without distant metastatic disease I-IL . Study Objectives This study aim provide rational evidence base appropriate management metastatic melanoma groin LNs , assess effect addition ipsilateral pelvic lymphadenectomy patient disease-free survival ( DFS ) , distant disease-free survival ( DDFS ) , overall survival ( OS ) , morbidity , quality life . In addition , study clarify reliability PET ( Positron Emission Tomography ) / CT ( Computed Tomography ) scan stag pelvic LNs , clarify morbidity difference operation balance cohort , evaluate health economic benefit I-IL IL provide tissue serum resource use identify biological marker recurrence progression inguinal metastasis . Study Hypothesis There significant difference DFS patient IL I-IL , conditional PET/CT scan show evidence pelvic disease time diagnosis groin LN metastatic melanoma . Study Population The aim recruit 634 patient 5 year 15 year old cytologically histologically confirm metastatic melanoma inguinal LNs ( H &amp; E &amp; IHC ) ; specifically evidence pelvic node involvement distant spread melanoma clinically PET/CT stag scan . To eligible patient must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0-2 randomisation . Study Treatments Eligible patient randomise 1:1 undergo IL I-IL . Study Design This international , multi-centre , phase III , non-inferiority , prospective , randomise clinical trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients may include study meet follow criterion : 1 . Must 15 . 2 . Have primary cutaneous melanoma patient present stage III melanoma know primary tumour thorough search primary document ( include perineal perianal area ) 3 . Life expectancy least 10 year time diagnosis , consider melanoma question , determine PI 4 . Must one multiple inguinal node ( ) involve , histologically cytologically proven metastatic melanoma . This detect : At time diagnosis ; Or Ultrasound detection ; Or later relapse Sentinel Node Biopsy ( SNB ) perform time primary tumour management ; Or result SNB ; Or time regional recurrence `` false negative '' SNB ; 5 . Absent distant disease clinically PET/CT scan . ( Patients must NO distant disease visceral metastasis ) 6 . ECOG performance status must 0 2 randomisation 7 . Whole body PET/CT scan , specifically state NO evidence pelvic lymph node involvement prior randomisation CT Brain MRI Brain . Scans must perform within 4 week randomisation . 8 . Able provide write , inform consent 9 . Willing return centre follow examination procedure , outline protocol . 10 . All patient must randomise undergo lymphadenectomy surgery 90 day follow diagnosis inguinal LN involvement 1 . Distant metastatic disease clinical examination stag imaging ( CT/MRI brain whole body PET/CT scan ) 2 . Pelvic LN involvement SNB PET/CT scan suggestive metastatic disease pelvis criterion diagnosis include normal size enlarge lymph node ( &gt; 1 cm ) increase FDG activity PET ( SUV &gt; 3 ) . If enlarge , necrotic lymph node FDG activity PET require present . If unsure central review seek . 3 . Bilateral inguinal lymph node involvement 4 . Patients history major pelvic surgery / regional radiotherapy time past 5 . Requiring plan radiotherapy follow surgery due macroscopic , bulky mat node . 6 . Unfit General Anaesthesia 7 . Melanomarelated operative procedure correspond criterion describe protocol 8 . Patients prior cancer , except : thin &lt; =1 mm , regionally unrelated melanoma &gt; 5 year ago good prognosis regionally unrelated cancer ( &gt; 90 % probability 10 year disease specific survival ) cancer diagnose five year ago evidence disease recurrence within time successfully treat basal cell squamous cell skin carcinoma carcinoma insitu cervix 9 . A medical psychiatric condition compromise ability give inform consent complete protocol 10 . Positive urine pregnancy test woman childbearing potential ( +/7 day randomisation onto trial )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>metastatic melanoma</keyword>
	<keyword>groin lymph node</keyword>
	<keyword>surgery</keyword>
	<keyword>lymphadenectomy</keyword>
</DOC>